Navigation Links
Percutaneous aortic valve replacement safe, successful in high-risk patients

Catheter techniques are expanding into new territory, successfully aiding in the replacement of narrowed, calcified aortic valves in patients too sick to withstand open-chest surgery. According to a study reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9?2, 2007, in Orlando, FL, patients who were treated with the CoreValve Revalving System (CoreValve, Irvine, CA) experienced improvements in both the size of the aortic valve and in the severity of heart failure.

To evaluate the CoreValve system, Anita Asgar, M.D., and her colleagues at Montreal Heart Institute recruited 17 elderly patients with a severely narrowed aortic valve, all of whom had been turned down for surgery because of other health problems. In severe narrowing, or stenosis, of the aortic valve, the heart has difficulty pumping blood from the left ventricle to the rest of the body. The result is a back-up of fluid into the lungs and severe shortness of breath with even minimal activity.

With the CoreValve system, aortic valve replacement is performed by threading a special delivery catheter through the femoral artery in the groin and into the aorta in a direction opposite, or retrograde, to the normal flow of blood. Once the catheter is properly positioned in the opening of the aortic valve, it is pulled back to release the CoreValve, a self-expanding stent-like frame with the new tissue valve attached to its core. As it expands, the CoreValve covers the diseased natural valve leaflets.

During the procedure, the patients were placed on a bypass pump for an average of 30?0 minutes to minimize blood flow through the aorta and ease placement of the replacement valve.

All 17 patients survived the procedure. One patient died 5 days later from stroke. Five additional patients died after discharge from the hospital from health problems unrelated to the replacement valve. Follow-up in the 11 survi vors showed that the average aortic valve area more than doubled, on average, following the procedure. In addition, the severity of heart failure significantly improved, as gauged by both B-type natriuretic peptide (NT-BNP), a protein produced by the ventricles of the heart during heart failure, and New York Heart Association (NHYA) classification. After the procedure, patients were ranked in NYHA class II, on average, suggesting most were able to engage in a moderate level of activity before becoming short of breath.
'"/>

Source:Society for Cardiovascular Angiography and Interventions


Related biology news :

1. Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host.
2. Bone and cartilage growth to blame for heart valve disease
3. Findings advance use of adult stem cells for replacement bone
4. Genes may determine success of hip replacement surgery
5. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
6. Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
7. New, automated tool successfully classifies and relates proteins in unprecedented way
8. Biomarkers isolated from saliva successfully predict oral and breast cancer
9. UN successfully tests green pesticide against locusts
10. Stem cell therapy successfully treats heart attack in animals
11. Mad cow proteins successfully detected in blood

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic ... to mergers and acquisitions (M&A), and Kalorama Information expects ... such acquisitions have been shifting. Generally, uncertainty in reimbursement ... and the U.S. has changed the acquisitions landscape. Instead ... resulted in companies buying partners outside of their home ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... UCHealth ( Aurora, Colorado ) ... nodule patient management. In addition to optimizing care coordination ... the lung, UCHealth looks to improve provider workflow by ... Stephanie Brown, RN , Thoracic Nurse Navigator, ... an Excel spreadsheet, which was extremely arduous and susceptible ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, ... study showed that aerosolized KL4 surfactant reduced lung ... preclinical animal model. The Company believes that these ... evidence that supports the role of KL4 surfactant ...
(Date:2/16/2017)... YORK , Feb. 16, 2017 Paradigm ... Series B financing, adding an additional $3M from New ... Mesa Verde Venture Partners and other strategic partners at ... towards further accelerating commercial adoption of their flagship Paradigm ... and expanding the Paradigm cancer registry. ...
Breaking Biology Technology: